MeCure Industries Secures Shareholder Approval for N50 Billion Capital Raise, Annual Profit Surges 177 Percent

Shareholders of MeCure Industries Plc have formally approved the company’s expanded capital-raising program, clearing the path for a N50 billion Rights Issue to fund regional expansion and reinforce working capital.The decision was sealed at the pharmaceutical manufacturer’s third Annual General Meeting in Lagos, where shareholders also approved a total dividend payout of N1.29 billion, translating to 32 kobo per ordinary share.

The capital boost follows a strong financial performance in 2025, where MeCure reported a 69 percent surge in full-year revenue to N77.69 billion compared to N46.03 billion recorded in 2024. Earnings before interest and tax nearly doubled to N16.43 billion, while net profit after tax rose 177 percent to N6.46 billion.

The company plans to deploy the fresh equity to buffer its balance sheet against elevated financing costs, foreign exchange volatility, and domestic inflationary pressures. Beyond short-term working capital, the funds will drive long-term manufacturing expansion across Nigeria and the broader West African market.

MeCure has also deepened its commercial footprint by securing regulatory clearance for 19 new pharmaceutical formulations across cardiovascular, anti-infective, and metabolic therapeutic areas, with four additional product applications currently undergoing final regulatory review.

Boardroom Voices Africa Insight

The decision by MeCure Industries to expand its equity base by N50 billion reflects a critical strategic pivot for African pharmaceutical boards navigating macroeconomic headwinds.

First, equity financing offsets high interest rates. In an environment where monetary tightening has elevated borrowing costs, raising equity capital through rights issues protects operating margins from aggressive debt service obligations.

Second, product diversification secures market share. Expanding therapeutic coverage into high-demand disease categories like cardiovascular and metabolic care creates resilient revenue streams while reducing national reliance on imported finished medicines.